Normal view MARC view ISBD view

A retrospective evaluation of the combination of erenumab and onabotulinum toxin A for the prevention of chronic migraine.

MedStar author(s):

Citation: Clinical Neurology & Neurosurgery. 215:107200, 2022 04.PMID: 35286994Department: MedStar Georgetown University Hospital/MedStar Washington Hospital Center | Neurology ResidencyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Drug-Related Side Effects and Adverse Reactions | *Migraine Disorders | Antibodies, Monoclonal, Humanized | Antibodies, Monoclonal, Humanized | Botulinum Toxins, Type A | Headache | Humans | Migraine Disorders/dt [Drug Therapy] | Migraine Disorders/pc [Prevention & Control] | Retrospective StudiesYear: 2022 ISSN:

0303-8467

Name of journal: Clinical neurology and neurosurgeryAbstract: CONCLUSION: This retrospective case series showed a reduction in monthly migraine and headache days with the treatment combination of erenumab and onabot A compared to onabot A alone in patients with chronic migraine. Copyright ♭ 2022 Elsevier B.V. All rights reserved.METHODS: This is a retrospective cohort study of patients with a diagnosis of chronic migraine receiving onabot A, who were additionally started on erenumab. Primary endpoint was a decrease in number of migraine days while on the combination treatment as compared to onabot A alone. Secondary endpoints included a decrease in headache days and reported side effects.OBJECTIVE: Prior to the approval of erenumab, onabotulinum toxin A (onabot A) was the only Food and Drug Administration-approved chronic migraine preventive treatment. In this study, we assess the safety and efficacy of the combination of erenumab and onabot A for chronic migraine prevention.RESULTS: When erenumab was added to onabot A, participants (n = 50) experienced significantly lower number of monthly migraine days (11.3 +/- 9.3 vs. 14.9 +/- 9.4, p < 0.001). The treatment of onabot A and erenumab also significantly lowered the number of monthly headache days (18.2 +/- 10.3 vs. 20.7 +/- 9.1, p = 0.042). There were no "severe" adverse effects reported in the combined treatment group.All authors: Ailani J, Dougherty CO, Nandyala AS, Suri HOriginally published: Clinical Neurology & Neurosurgery. 215:107200, 2022 04.Fiscal year: FY2022 Digital Object Identifier:

https://dx.doi.org/10.1016/j.clineuro.2022.107200

Date added to catalog: 2022-05-11

Holdings ( 1 )
Title notes ( 5 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	35286994	Available		35286994

CONCLUSION: This retrospective case series showed a reduction in monthly migraine and headache days with the treatment combination of erenumab and onabot A compared to onabot A alone in patients with chronic migraine. Copyright ♭ 2022 Elsevier B.V. All rights reserved.

METHODS: This is a retrospective cohort study of patients with a diagnosis of chronic migraine receiving onabot A, who were additionally started on erenumab. Primary endpoint was a decrease in number of migraine days while on the combination treatment as compared to onabot A alone. Secondary endpoints included a decrease in headache days and reported side effects.

OBJECTIVE: Prior to the approval of erenumab, onabotulinum toxin A (onabot A) was the only Food and Drug Administration-approved chronic migraine preventive treatment. In this study, we assess the safety and efficacy of the combination of erenumab and onabot A for chronic migraine prevention.

RESULTS: When erenumab was added to onabot A, participants (n = 50) experienced significantly lower number of monthly migraine days (11.3 +/- 9.3 vs. 14.9 +/- 9.4, p < 0.001). The treatment of onabot A and erenumab also significantly lowered the number of monthly headache days (18.2 +/- 10.3 vs. 20.7 +/- 9.1, p = 0.042). There were no "severe" adverse effects reported in the combined treatment group.

English